Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Hospital Universitario Reina Sofía, Cordoba, Spain.
Renal, Vascular and Diabetes Research Lab, Fundación Instituto de Investigaciones Sanitarias-Fundación Jiménez Díaz, Autonoma University, Madrid, Spain.
Biomed Pharmacother. 2023 Dec 31;169:115925. doi: 10.1016/j.biopha.2023.115925. Epub 2023 Nov 25.
Rhabdomyolysis is a severe clinical syndrome associated to acute kidney injury (AKI) and chronic kidney disease (CKD). TWEAK/Fn14 signaling axis regulates renal inflammation and tubular cell death. However, the functional role of TWEAK/Fn14 in rhabdomyolysis remains unknown.
Rhabdomyolysis was induced in wild-type, TWEAK- and Fn14-deficient mice or mice treated with TWEAK blocking antibody. Renal injury, inflammation, fibrosis and cell death were assessed. Additionally, we performed in vivo and in vitro studies to explore the possible signalling pathways involved in Fn14 regulation.
Fn14 renal expression was increased in mice with rhabdomyolysis, correlating with decline of renal function. Mechanistically, myoglobin (Mb) induced Fn14 expression via ERK and p38 pathway, whereas Nrf2 activation diminished Mb-mediated Fn14 upregulation in cultured renal cells. TWEAK or Fn14 genetic depletion ameliorated rhabdomyolysis-associated loss of renal function, histological damage, tubular cell death, inflammation, and expression of both tubular and endothelial injury markers. Deficiency of TWEAK or Fn14 also decreased long-term renal inflammation and fibrosis in mice with rhabdomyolysis. Finally, pharmacological treatment with a blocking TWEAK antibody diminished the expression of acute renal injury markers and cell death and lessened residual kidney fibrosis and chronic inflammation in rhabdomyolysis.
TWEAK/Fn14 axis participates in the pathogenesis of rhabdomyolysis-AKI and subsequent AKI-CKD transition. Blockade of this signaling pathway may represent a promising therapeutic strategy for reducing rhabdomyolysis-mediated renal injury.
Spanish Ministry of Science and Innovation, ISCIII and Junta de Andalucía.
横纹肌溶解症是一种与急性肾损伤(AKI)和慢性肾脏病(CKD)相关的严重临床综合征。TWEAK/Fn14 信号轴调节肾脏炎症和肾小管细胞死亡。然而,TWEAK/Fn14 在横纹肌溶解症中的功能作用尚不清楚。
在野生型、TWEAK-和 Fn14 缺陷型小鼠或用 TWEAK 阻断抗体治疗的小鼠中诱导横纹肌溶解症。评估肾脏损伤、炎症、纤维化和细胞死亡。此外,我们进行了体内和体外研究,以探讨 Fn14 调节中涉及的可能信号通路。
在横纹肌溶解症小鼠中,Fn14 在肾脏中的表达增加,与肾功能下降相关。从机制上讲,肌红蛋白(Mb)通过 ERK 和 p38 途径诱导 Fn14 表达,而 Nrf2 激活可减少 Mb 介导的 Mb 培养的肾细胞中 Fn14 的上调。TWEAK 或 Fn14 基因缺失可改善横纹肌溶解症相关的肾功能丧失、组织学损伤、肾小管细胞死亡、炎症以及肾小管和内皮损伤标志物的表达。TWEAK 或 Fn14 的缺乏也减少了横纹肌溶解症小鼠的长期肾脏炎症和纤维化。最后,用 TWEAK 阻断抗体进行药物治疗可减少急性肾损伤标志物的表达和细胞死亡,并减轻横纹肌溶解症后的残余肾纤维化和慢性炎症。
TWEAK/Fn14 轴参与横纹肌溶解症-AKI 的发病机制和随后的 AKI-CKD 转化。阻断该信号通路可能是减少横纹肌溶解症介导的肾脏损伤的一种有前途的治疗策略。
西班牙科学与创新部、ISCIII 和安达卢西亚大区政府。